Abhit Singh and Adam Torres discuss Intrommune Therapeutics.
Apply to be a guest on our podcast here
Abhit Singh, MD, MHA , VP Medical Affairs, Ex- Chief Regulatory Officer at Intrommune Therapeutics
Intrommune Therapeutics is looking to bring new hope to those suffering from peanut allergies. In this episode, Adam Torres and Abhit Singh, MD, MHA , VP Medical Affairs, Ex- Chief Regulatory Officer at Intrommune Therapeutics, explore the trajectory of Intrommune Therapeutics and the future of it’s products.
About Abhit Singh
Dynamic Global Physician Leader, Renegade Thinker and Speaker – specializing in the Medical Advisory, Transactional and Transformational Management of Biotech and Healthcare organizations. Expert in spearheading cross-functional teams in a matrix ecosystem towards realizing strategic project goals. Have a talent for ensuring alignment, synergy, and synchronicity towards an organization’s mission, values, and vision.
About Intrommune Therapeutics
Intrommune Therapeutics is a specialty biopharmaceutical company located in New York, NY. Intrommune is developing a revolutionary new treatment platform for food allergies that is safe, effective and convenient. Intrommune’s first product is a therapy for patients who suffer from peanut allergy.
Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 9 million U.S. adults and 6 million U.S. children, who suffer from this life-altering condition.